Renaissance Capital’s Royalty Pharma RPRX Stock Holding History

Renaissance Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-123,913	Closed	-$4.46M	–	84
2023 Q1	$4.46M	Sell	123,913 -13,549	-10%	-$502K	3.31%	7
2022 Q4	$5.43M	Sell	137,462 -2,428	-2%	-$101K	4.24%	4
2022 Q3	$5.62M	Sell	139,890 -26,150	-16%	-$1.12M	3.61%	4
2022 Q2	$6.98M	Buy	166,040 +63,988	+63%	+$2.62M	3.72%	8
2022 Q1	$3.98M	Sell	102,052 -30,561	-23%	-$1.2M	1.69%	17
2021 Q4	$5.29M	Sell	132,613 -23,235	-15%	-$903K	1.36%	23
2021 Q3	$5.63M	Sell	155,848 -224,213	-59%	-$8.71M	1.14%	24
2021 Q2	$15.6M	Sell	380,061 -72,887	-16%	-$3.1M	2.46%	14
2021 Q1	$19.8M	Buy	452,948 +256,158	+130%	+$12.1M	2.93%	9
2020 Q4	$9.85M	Buy	+196,790	New	+$8.35M	1.35%	23

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Capital's RPRX Position: Q2 2023 in Review

Renaissance Capital sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 123,913 shares — an estimated $4.46M sold.

Renaissance Capital first reported a position in RPRX in Q4 2020 and held it in 10 quarters. The position peaked at $19.8M in Q1 2021. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Renaissance Capital reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Renaissance Capital sold 123,913 Royalty Pharma shares in Q2 2023, an estimated $4.46M.
Renaissance Capital first reported a position in Royalty Pharma in Q4 2020 and held it in 10 quarters.
Renaissance Capital's Royalty Pharma position peaked at $19.8M in Q1 2021.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Renaissance Capital's 13F filing for Q2 2023, filed 17 Jul 2023.